[1] *Exosomes Laboratory, Center for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), Derio, Spain*
[2] *Proteomics Platform. Center for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), Derio, Spain*
[3] *Servicio de Aparato Digestivo, Hospital Universitario de Basurto, Bilbao Vizcaya, España*
[4] *Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain*
[5] *Ikerbasque Basque Foundation for Science Bilbao Spain*

Introduction: Alcohol abuse has a high impact on the mortality and morbidity related to a great number of diseases and is responsible for the development of alcoholic liver disease (ALD). It remains challenging to detect and evaluate its severity, which is crucial for prognosis.

Objective: In this work, we studied if urinary EVs (uEVs) could serve in diagnose and evaluate cirrhosis in ALD.

Methods: uEVs characterization by cryo-electron microscopy (Cryo-EM), Nanoparticle Tracking Analysis (NTA) and Western blotting (WB) was performed in a cohort of 21 controls and 21 cirrhotic patients. Then, proteomics of urinary EVs (uEVs) was carried out in a second cohort of 6 controls and 8 patients in order to identify new putative biomarkers for cirrhosis in ALD.

Results: uEVs concentration, size and composition were altered in cirrhotic patients. A total of 1304 proteins were identified in uEVs, and 90 of them were found to be altered in cirrhotic patients.

Conclusions: uEVs could be considered as a tool and a supplier of new biomarkers for ALD, whose application would be especially relevant in chronic patients. Yet, further research is necessary to obtain more relevant result in clinical terms.

P-67 ULTRASOUND GUIDED TRANSIENT ELASTOGRAPHY FOR THE DIAGNOSIS AND STAGING OF LIVER FIBROSIS

Juan Francisco Rozas, Katherine González, Luis Salazar, Máximo Cattaneo, Juan Pablo Roblero, Alvaro Urzúa, Alexandra Sandoval, Jaime Poniachik

Servicio de Gastroenterología, Hospital Clínico de la Universidad de Chile, Santiago, Chile

Introduction: Transient elastography (TE) is a non-invasive method for the evaluation of liver fibrosis. Up to 20% of measurements fail, possibly due to the choice of probe position.

Objectives: To evaluate the use of ultrasound as a position guide (UPG) prior to TE to improve the measurement of liver stiffness (LS).

Methods: Prospective study of 237 patients (age 54 ± 14 years, 69% women) referred for TE (FibroScan, Echosens). The main indication was non-alcoholic fatty liver disease (52.3%). 65.4% of the patients were overweight or obese. LS was measured in each patient according to the manufacturer's recommendations and at the same appointment, in UPG. Fibrosis staging sections recommended by the manufacturer were used. Statistical analyzes performed with chi-square and t-test ($p < 0.05$).

Results: The mean LS with UPG was 7.6 (3.0-55.7) kPa. In 50 patients (21.1%) the measurement of LS failed without the use of ultrasound. There was not when using UPG. In the 187 patients with TE without ultrasound, IQR / LSM <10% was obtained in 67.3%. When UPG was used, it was obtained in 89% (p = 0.001). When comparing the fibrosis stage, in 21.4% of the cases it was modified when using UPG; in 15% it changed from significant or advanced fibrosis (F2-F4) to non-significant (F0-F1), or vice versa.

Conclusion: The use of UPG before TE improved the success rate and reliability of the LS measurement, improving fibrosis staging.

P-68 FREQUENCY AND FACTORS ASSOCIATED WITH ANTIBIOTIC DE-ESCALATION IN PATIENTS WITH CIRRHOSIS AND BACTERIAL INFECTIONS

Maria Nelly Gutierrez Acevedo[1], Sabrina Barbero[2], Lorena del Carmen Notari[2], Marina Agozino[3], Jose Luis Fernandez[3], Silvina Tevez[3], Maria Margarita Anders[4], Nadia Grigera[4], Florencia Antinucci[4], Orlando Orozco Ganem[4], Maria Dolores Murga[5], Daniea Perez[5], Ana Palazzo[5], Liria Martinez Rejtman[6], Ivonne Giselle Duarte[7], Julio Vorobioff[8], Victoria Trevizan[8], Sofía Bulaty[8], Fernando Bessone[8], José Daniel Bosia[9], Silvia Mabel Borzi[9], Teodoro E. Stieben[10], Adriano Masola[10], Sebastian Eduardo Ferretti[11], Agñel Ramos[11], Diego Arufe[12], Ezequiel Demirdjian[12], Maria Pia Raffa[12], Cintia Elizabet Vazquez[13], Pablo Ruiz[13], José Emanuel Martínez[14], Hugo Fainboim[15], Mirta Peralta[15], Leandro Alfredo Heffner[16], Andrea Odzak[16], Andres Bruno[16], Melisa Dirchwolf[17], Jesica Tomatis[17], Astrid Smud[18], Manuel Mendizabal[19], Josefina Pages[19], Carla Bellizzi[20], Ana Martinez[20], Diego Giunta[21], Marcelo Valverde[22,23], Martin Elizondo[22,23], Ezequiel Mauro[24], Adrian Gadano[21,24], Sebastián Marciano[21,24]

[1] *Clinica Chapelco, San Martin de los Andes, Argentina*
[2] *Hospital Churruca Visca, CABA, Argentina*
[3] *Sanatorio Güemes, CABA, Argentina*
[4] *Hospital Aleman, CABA, Argentina*
[5] *Hospital A.C. Padilla, San Miguel de Tucuman, Argentina*
[6] *Hospital T J Schestakow, Mendoza, Argentina*
[7] *Hospital 4 de Junio, Sáenz Peña, Argentina*
[8] *Hospital Centenario, Rosario, Argentin*
[9] *Hospital Rossi, La Plata, Argentina*
[10] *Hospital San Martín, Paraná, Argentina*
[11] *Sanatorio Parque, Rosario, Argentina*
[12] *Sanatorio Sagrado Corazón, CABA, Argentina*
[13] *Hospital Regional de Río Gallegos, Río Gallegos, Argentina*
[14] *Sanatorio Boratti, Posadas, Argentina*
[15] *Hospital Muñiz, CABA, Argentina*
[16] *Hospital Argerich, CABA, Argentina*
[17] *Hospital Privado de Rosario, Rosario, Argentina*
[18] *Hospital Italiano de Buenos Aires, Infectious Diseases Section, CABA, Argentina*
[19] *Hospital Universitario Austral, Pilar Centro, Argentina*
[20] *Hospital Fernández, CABA, Argentina*
[21] *Hospital Italiano de Buenos Aires, Department of Research, CABA, Argentina*
[22] *Hospital de Clínicas, Montevideo, Uruguay*
[23] *Hospital Militar, Montevideo, Uruguay*
[24] *Hospital Italiano de Buenos Aires, Liver Unit, CABA, Argentina*

Background: Antibiotic de-escalation is considered a safe strategy that reduces costs and the risk of multi-drug resistant infections. However, its prevalence and associated factors in real-life practice were not reported in patients with cirrhosis in Latin-America.

Aims: To estimate the prevalence of antibiotic de-escalation in patients with cirrhosis in real life-practice, and to explore its associated factors.

Methods: We performed an analysis of the multicenter prospective cohort study of cirrhotic patients with bacterial infections throughout Argentina and Uruguay (clinicatrials.gov NCT03919032). Patients who died in the first 72 hs from the diagnosis of the infection were excluded. In accordance with guidelines, de-escalation was defined as changing the initially antimicrobials to a narrower spectrum regimen, or suspending one or more of the empirical antibiotics, according to culture results or to other clinical reasons, either in patients with culture-positive or culture-negative bacterial infections. We used inverse probability weighting (IPW) of having a culture-positive infection to estimate its causal effect on de-escalation.

Results: We included 450 patients. Most frequent infections were SBP (30.4%), and urinary tract infection (12.9%). Overall, 243 (54%) infections were culture-positive, and 207 (46%) culture-negative. De-escalation was reported in 85 patients (18.9%: 95% CI 15%-22%) at a mean of 3.3 ± 2.4 days from treatment initiation and was more frequent in culture-positive than culture-negative infections (28.4% vs 7.7%, p< 0.001). The table shows the crude analyses of variables associated with de-escalation. Culture-positive infection was strongly and independently associated with de-escalation (OR_{IPW} 6.08; 95% CI: 2.90-12.70; p < 0.001).

Conclusions: Antibiotic de-escalation was reported in one-fifth of in-patients with cirrhosis. Given that having a culture-positive infection had a strong effect on de-escalation, efforts should be made to increase the likelihood of obtaining adequate culture samples in a timely manner.

Table
Univariate analyses of factors associated with antibiotic de-escalation (n=450).

Variable	All (N=450)	Non de-escalated (N=365)	De-escalated (N=85)	OR (CI 95%)	p
Age (years), media (SD)	57.6 (12.6)	57.5 (12.8)	58 (11.6)	1.01 (0.98-1.02)	0.819
Male gender, num (%)	299 (66.4)	249 (68.2)	50 (58.8)	0.66 (0.4-1.1)	0.100
Cirrhosis etiology, num (%)[a]					
Viral	70 (15.6)	59 (16.2)	11 (12.9)	Ref	Ref
Alcohol	193 (42.9)	157 (43.2)	36 (42.3)	1.23 (0.59-2.57)	0.583
NASH	92 (20.5)	73 (20)	19 (22.4)	1.39 (0.62-3.16)	0.424
Cryptogenic	60 (13.4)	47 (12.9)	13 (15.3)	1.48 (0.61-3.61)	0.385
Other	34 (7.6)	28 (7.7)	6 (7.1)	1.14 (0.38-3.42)	0.803
Diabetes, num (%)	142 (31.7)	111 (30.5)	31 (36.9)	1.33 (0.81-2.18)	0.256
Child-Pugh score, media (SD)	9.8 (2.3)	9.9 (2.3)	9.8 (2.4)	0.98 (0.9-1.1)	0.713
MELD-Na Score, media (SD)[b]	19.8 (7.1)	19.7 (7.1)	20 (7.1)	1.01 (0.9-1.01)	0.711
SIRS at infection, num (%)[c]	134 (30.1)	98 (27)	36 (43.9)	2.11 (1.29-3.47)	0.003
Hospitalization in critical unit, num (%)[d]	100 (22.4)	76 (20.9)	24 (28.6)	1.51 (0.88-2.58)	0.132
ACLF, num (%)	127 (28.2)	100 (27.4)	27 (31.8)	1.23 (0.74-2.05)	0.421
Type of infection, num (%)					
Community acquired	237 (52.7)	202 (55.3)	35 (41.2)	Ref	Ref
HCA	98 (21.8)	74 (20.3)	24 (28.2)	1.87 (1.04-3.35)	0.035
Nosocomial	115 (25.6)	89 (24.4)	26 (30.6)	1.69 (0.96-2.97)	0.070
Site of infection, num (%)					
SBP	137 (30.4)	124 (34)	13 (15.3)	Ref	Ref
UTI	112 (24.9)	84 (23)	28 (32.9)	3.18 (1.56-6.49)	0.001
Pneumonia	58 (12.9)	49 (13.4)	9 (10.6)	1.75 (0.70-4.36)	0.228
Spontaneous bacteremia	33 (7.4)	21 (5.8)	12 (14.1)	5.45 (2.19-13.55)	<0.001
Other	110 (24.4)	87 (23.8)	23 (27.1)	2.52 (1.21-5.25)	0.013
Culture-positive infection, num (%)	243 (54)	174 (47.7)	69 (81.2)	4.73 (2.64-8.46)	<0.001
Adequate initial antibiotic, num (%)[a]	358 (79.7)	289 (79.4)	69 (81.2)	1.12 (0.61-2.04)	0.713
Infection by MDRO, num (%)	98 (21.8)	77 (21.1)	21 (24.7)	1.23 (0.71-2.13)	0.468

SD: Standard deviation. NASH nonalcoholic steatohepatitis. MELD-NA: Model for End-Stage Liver Disease-Sodium. SIRS: systemic inflammatory response syndrome. ACLF: Acute-on-chronic liver failure. HCA: Health care associated. SBP: Spontaneous bacterial peritonitis. UTI: Urinary tract infection. MDRO: multidrug-resistant organism. a) Available in 449 patients. b) Available in 442 patients. c) Available in 445 patients. d) Available in 447 patients. Univariate logistic regression was used for comparisons.

P-69 RELATION BETWEEN CLINICAL AND ELASTOGRAPHIC CHARACTERISTICS OF CIRRHOTIC PATIENTS WITH ENDOSCOPIC VARICEAL LIGATION: A SINGLE-CENTER EXPERIENCE IN LIMA, PERU

Jorge Garavito-Rentería[1],
Rommel Zambrano-Huailla[2],
William J. Araujo-Banchon[3]

[1] *Unidad de Hígado, Hospital Nacional Arzobispo Loayza, Lima, Perú*
[2] *Servicio de Gastroenterología, Hospital III de Emergencias Grau EsSalud, Lima, Perú*
[3] *Grupo de Investigación Continental, Universidad Continental, Lima, Perú*

Background: Endoscopic variceal ligation (EVL) is the first-line therapy for one of the most frequent causes of mortality in liver cirrhosis, the gastrointestinal bleeding. Child-Pugh, MELD-Na score and transient elastography are noninvasive evaluation of liver cirrhosis. The purpose of the study is to describe and analyze the relation between clinical and elastographic features of cirrhotic patients with EVL.

Methods: Observational and analytical study. Clinical, biochemical, etiologic and elastographic characteristics of 153 cirrhotic patients with EVL admitted to the Gastroenterology Service of Hospital Nacional Arzobispo Loayza between 2017 and 2019 were analyzed using Kruskall Wallis and Mann-Whitney test.

Results: Among the 153 patients treated with EVL, 51.6% were male and 59.6% were older than 60 years. NAFLD (59.5%) was the most frequent cause of liver cirrhosis. Complications of all EVL sessions represented 5.88% (transient chest pain). Child-Pugh B (30 kPa, $p = 0.0016$) and MELD-Na score ≥ 15 (32.90 kPa, $p = 0.0003$) showed greater values of liver stiffness. No statistical difference was found in the liver stiffness measurements in relation to etiology of liver disease.

Conclusions: Decompensated cirrhosis with EVL has greater values of liver stiffness.

Keywords: Liver Cirrhosis, Esophageal Varices, Elastography, Endoscopy

Table
Comparison of the liver stiffness measurement in relation to etiology, Child-Pugh and MELD-Na score

	Transient Elastography (kPa)**	P value*
Etiology		
NAFLD	24.00 (16.90)	0.3063
ALD	26.30 (25.90)	
Autoimmune hepatitis	18.20 (9.20)	
Viral hepatitis	25.80 (15.60)	
Child-Pugh		
A	21.15 (16.50)	0.0016*
B	30.00 (23.90)	
C	27.00 (11.50)	
MELD-Na score		
< 15	21.30 (17.60)	0.0003†
≥ 15	32.90 (23.20)	

* Kruskal-Wallis test
** Median and interquartile range
† Mann-Whitney test
NAFLD, Non-alcoholic Fatty Liver Disease; ALD, Alcoholic Liver Disease; MELD-Na, modified Model for End-Stage Liver Disease including sodium